Drug intelligence / Profile preview

SFT-008

Development stage: Unknown
Lead developer: invoX Pharma
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

SFT-008 is an investigational inhaled therapeutic being developed by Softhale (a subsidiary of invoX Pharma) for the treatment of cystic fibrosis (CF). The drug is delivered using the proprietary Softhaler® platform, which is a propellant-free, multi-dose soft mist inhaler (SMI) designed to optimize lung deposition and improve patient adherence through ease of use. While the specific active pharmaceutical ingredient and molecular target for SFT-008 have not been publicly disclosed, it is part of a broader pipeline of respiratory treatments utilizing the Softhaler® technology to deliver medications deep into the lungs with high efficiency. The program is currently in early clinical development.

Beyond the preview

Go deeper on SFT-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFT-008.

Explore the full profile